Search Results - Nils Debus
- Showing 1 - 4 results of 4
-
1
Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients by Ali Afshar‐Oromieh, Marcelo Livorsi da Cunha, Jairo Wagner, Uwe Haberkorn, Nils Debus, Wolfgang Weber, Matthias Eiber, Tim Holland‐Letz, Isabel Rauscher
Published 2021Artigo -
2
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095 by Ali Afshar‐Oromieh, Uwe Haberkorn, Christian M. Zechmann, Thomas Armor, Walter Mier, Fabian Spohn, Nils Debus, Tim Holland‐Letz, John W. Babich, Clemens Kratochwil
Published 2017Artigo -
3
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer by Ali Afshar‐Oromieh, Nils Debus, Monika Uhrig, Thomas A. Hope, Michael J. Evans, Tim Holland‐Letz, Frederik L. Giesel, Klaus Kopka, Boris Hadaschik, Clemens Kratochwil, Uwe Haberkorn
Published 2018Artigo -
4
Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients by Ali Afshar‐Oromieh, Tim Holland‐Letz, Frederik L. Giesel, Clemens Kratochwil, Walter Mier, Sabine Haufe, Nils Debus, Matthias Eder, Michael Eisenhut, Martin Schäfer, Oliver Neels, Markus Hohenfellner, Klaus Kopka, Hans‐Ulrich Kauczor, Jürgen Debus, Uwe Haberkorn
Published 2017Artigo
Search Tools:
Related Subjects
Cancer
Internal medicine
Medicine
Prostate cancer
Nuclear medicine
Prostate
Radiology
Urology
Androgen deprivation therapy
Biochemical recurrence
Cohort
Oncology
PET-CT
Pathological
Positron emission tomography
Prostatectomy
Retrospective cohort study
Biology
Multivariate analysis
Paleontology
Prostate-specific antigen
Radiation therapy
Radioligand
Radionuclide therapy
Receptor
Stage (stratigraphy)
Toxicity